BMS Details Patient Death in Zola-Cel Multiple Sclerosis Trial - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

BMS Details Patient Death in Zola-Cel Multiple Sclerosis Trial

The company also reported early efficacy and safety data from the Phase I Breakfree-2 study

  • November 3, 2026

  • 3 min

Share

Original Source(s)

BMS Details Patient Death in Zola-Cel Multiple Sclerosis Trial

  • November 3, 2026

Related Content

Impact of genetic polymorphisms in the interleukin-18 and interleukin-21 genes on the risk and clinical outcomes of multiple sclerosis

Cognitive Function and Fatigue in Stable Multiple Sclerosis: EDSS and MRI Assessments Surpass Serum Biomarkers

From Marginal to Central: Marginal Zone-like B Cells as Critical Targets in Cladribine-Treated Multiple Sclerosis